Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 950

1.

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.

Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.

Arch Dermatol. 2007 Jun;143(6):719-26.

PMID:
17576937
2.

Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.

van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.

Br J Dermatol. 2008 Nov;159(5):1177-85. doi: 10.1111/j.1365-2133.2008.08771.x. Epub 2008 Jul 31.

PMID:
18673365
3.

Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.

Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A.

Br J Dermatol. 2007 Jan;156(1):138-42.

PMID:
17199580
4.

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.

Br J Dermatol. 2005 Dec;153(6):1192-9.

PMID:
16307657
5.

Etanercept treatment for children and adolescents with plaque psoriasis.

Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A; Etanercept Pediatric Psoriasis Study Group.

N Engl J Med. 2008 Jan 17;358(3):241-51. doi: 10.1056/NEJMoa066886.

6.

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.

Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L; Etanercept Psoriasis Study Group.

Br J Dermatol. 2005 Jun;152(6):1304-12.

PMID:
15948997
7.

Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.

Landells I, Paller AS, Pariser D, Kricorian G, Foehl J, Molta C, Freundlich B.

Eur J Dermatol. 2010 May-Jun;20(3):323-8. doi: 10.1684/ejd.2010.0911. Epub 2010 Feb 25.

PMID:
20185386
8.

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.

Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.

Dermatology. 2009;219(3):239-49. doi: 10.1159/000237871. Epub 2009 Sep 10.

PMID:
19752505
9.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

10.

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.

Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR.

J Am Acad Dermatol. 2007 Apr;56(4):598-603. Epub 2006 Nov 17.

PMID:
17113190
11.

A randomized trial of etanercept as monotherapy for psoriasis.

Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R.

Arch Dermatol. 2003 Dec;139(12):1627-32; discussion 1632.

PMID:
14676082
12.

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2003 Jun;48(6):1667-75.

13.

Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.

Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, Chiou CF, Dunn M, Jahreis A.

J Drugs Dermatol. 2010 Aug;9(8):928-37.

PMID:
20684143
14.

Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.

Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.

J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S101-11.

PMID:
16488320
15.
16.

Etanercept as monotherapy in patients with psoriasis.

Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB; Etanercept Psoriasis Study Group.

N Engl J Med. 2003 Nov 20;349(21):2014-22.

17.

Long-term etanercept in pediatric patients with plaque psoriasis.

Paller AS, Siegfried EC, Eichenfield LF, Pariser D, Langley RG, Creamer K, Kricorian G.

J Am Acad Dermatol. 2010 Nov;63(5):762-8. doi: 10.1016/j.jaad.2010.04.004. Epub 2010 Jun 3.

PMID:
20605256
18.

Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.

Gisondi P, Del Giglio M, Cotena C, Girolomoni G.

Br J Dermatol. 2008 Jun;158(6):1345-9. doi: 10.1111/j.1365-2133.2008.08564.x. Epub 2008 Apr 10.

PMID:
18410408
19.

Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.

Mazzotta A, Esposito M, Costanzo A, Chimenti S.

Am J Clin Dermatol. 2009;10(5):319-24. doi: 10.2165/11310770-000000000-00000.

PMID:
19658444
20.

Two years of experience with etanercept in recalcitrant psoriasis.

Ahmad K, Rogers S.

Br J Dermatol. 2007 May;156(5):1010-4. Epub 2007 Apr 4.

PMID:
17408393

Supplemental Content

Support Center